Identification of psychoplastogenic isoDMT analogs is a concrete step forward in using psychedelics for treating patients who suffer from depression.
The MEQ is a self-report measure that provides insight into a key aspect of the psychedelic experience.
Psychedelic medicine continues to move forward, but minority communities are being left behind.
The characterization of methoxetamine, a ketamine analog, and how its action on the serotonin system sets it apart.
Psychedelic-assisted psychotherapy leads the way in 2020’s top psychedelic papers.
The monoamine hypothesis of depression leaves many patients without effective help. It’s time for a paradigm shift, and psychedelics may be leading the way.
Feasibility, safety, and potential efficacy of psilocybin-assisted group therapy was demonstrated in treating demoralization in this marginalized population.
New research shows that ketamine reduces self-dislike, loosening the rigid prejudice toward oneself that can constitute depression.
Experiential avoidance is one transdiagnostic process that may be implicated in the therapeutic benefits of psychedelics.
While ketamine produces a whole symphony of effects in the brain, surprisingly, a localized neural oscillation in a lesser-known area of the brain is enough to cause feelings of dissociation.